Capital Research Global Investors
CDLX icon

Capital Research Global Investors’s Cardlytics CDLX Stock Holding History

Capital Research Global Investors’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,000
Closed -$11M – 440
2021
Q1 		$11M Hold
10,000
– – ﹤0.01% 404
2020
Q4 		$14.3M Hold
10,000
– – ﹤0.01% 383
2020
Q3 		$7.06M Buy
+10,000
New +$7.27M ﹤0.01% 385

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACM
Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return

Capital Research Global Investors's CDLX Position: Q2 2021 in Review

Capital Research Global Investors sold out of Cardlytics (CDLX) in Q2 2021, closing a stake of 10,000 shares — an estimated $11M sold.

Capital Research Global Investors first reported a position in CDLX in Q3 2020 and held it in 3 quarters. The position peaked at $14.3M in Q4 2020. 189 funds tracked by Wall St. Rank hold CDLX as of Q2 2021.

  • Capital Research Global Investors reported no remaining Cardlytics position as of Q2 2021 after selling out during the quarter.
  • Capital Research Global Investors sold 10,000 Cardlytics shares in Q2 2021, an estimated $11M.
  • Capital Research Global Investors first reported a position in Cardlytics in Q3 2020 and held it in 3 quarters.
  • Capital Research Global Investors's Cardlytics position peaked at $14.3M in Q4 2020.
  • 189 funds tracked by Wall St. Rank held Cardlytics as of Q2 2021.

Based on Capital Research Global Investors's 13F filing for Q2 2021, filed 16 Aug 2021.